^
Association details:
| Biomarker: | FLT3-ITD mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | pracinostat (SB939) (HDAC inhibitor) + Vonjo (pacritinib) (JAK2 inhibitor, FLT3 inhibitor, CSF-1R inhibitor, ACVR1 inhibitor, IRAK-1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML
Excerpt:
...the combination of pracinostat and pacritinib was also tested in mice bearing FLT3-ITD-driven MOLM-13 s.c. xenografts. In vitro data showed that the MOLM-13 cells were the most sensitive to both pracinostat and pacritinib,9 and that the synergy of combination treatment was greater than in SET-2 cells...
DOI:
https://dx.doi.org/10.1038%2Fbcj.2012.14
